C. Zerbini

发表

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

P. Delmas, S. Epstein, C. Recknor, 2009, Clinical therapeutics.

Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE

C. Bao, D. He, Jian-hua Xu, 2020, Rheumatology and Therapy.

Teriparatide vs risedronate for osteoporosis – Authors' reply

P. Geusens, S. Minisola, D. Kendler, 2018, The Lancet.

Effects of Up to 5 Years of Denosumab Treatment on Bone Histology and Histomorphometry: The FREEDOM Study Extension

Jacques P. Brown, I. Reid, P. Miller, 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

An updated hip fracture incidence rate for Brazil: the Brazilian Validation Osteoporosis Study (BRAVOS)

J. Kanis, E. McCloskey, M. McClung, 2022, Archives of Osteoporosis.

Definition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Association of Bone Assessment and Metabolism (ABRASSO)

V. Szejnfeld, B. C. Silva, F. Bandeira, 2022, Archives of endocrinology and metabolism.

Evidence based Latin American Guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update

C. Campusano, M. Lazaretti-Castro, O. Messina, 2022, Aging Clinical and Experimental Research.

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.

C. Christiansen, A. Harris, P. Alexandersen, 2016, JAMA.

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70

A. Schaefer, Shinn-Jang Hwang, G. Icardi, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Romosozumab Treatment in Postmenopausal Women with Osteoporosis.

A. Grauer, L. Hofbauer, E. Lau, 2016, The New England journal of medicine.

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.

D. Kiel, M. Sabatine, J. Reginster, 2019, The lancet. Diabetes & endocrinology.

Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study

C. Bao, Xiangpei Li, Xiao Zhang, 2021, Therapeutic advances in musculoskeletal disease.

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine

P. Dormitzer, N. Kitchin, A. Gurtman, 2022, The New England journal of medicine.

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

Hyo Youl Kim, Kenjiro Nakamura, A. Schaefer, 2022, Open forum infectious diseases.

Tofacitinib With Methotrexate in Third‐Line Treatment of Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Trial

V. Strand, C. Mebus, G. Burmester, 2015, Arthritis care & research.

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial

P. Geusens, E. Lespessailles, P. López-Romero, 2017, The Lancet.

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures

S. Cummings, C. Christiansen, E. Vittinghoff, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Romosozumab Improves Lumbar Spine Bone Mass and Bone Strength Parameters Relative to Alendronate in Postmenopausal Women: Results From the ARCH Trial.

Jacques P. Brown, T. Keaveny, K. Engelke, 2021, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome

A. Grauer, E. Lewiecki, S. Ferrari, 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study).

C. Cannon, L. Laine, P. Emery, 2009, Rheumatology.

Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group

J. Bilezikian, P. Miller, P. Ebeling, 2019, Osteoporosis International.

Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial

P. Geusens, E. Lespessailles, P. López-Romero, 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active‐Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial

Jacques P. Brown, T. Keaveny, K. Engelke, 2021, Journal of Bone and Mineral Research.

Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial

P. Geusens, E. Lespessailles, P. López-Romero, 2020, Osteoporosis International.

Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial

P. Geusens, E. Lespessailles, P. López-Romero, 2019, Archives of Osteoporosis.

Chronic arthritides and bone structure: focus on rheumatoid arthritis—an update

N. Lane, G. Adami, O. Messina, 2023, Aging Clinical and Experimental Research.

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial

P. Geusens, E. Lespessailles, P. López-Romero, 2017, The Lancet.

Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5‐Year Data From the Phase 3 Long‐Term Odanacatib Fracture Trial (LOFT) and its Extension

L. Duong, R. Recker, D. Dempster, 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Is it ethical to use placebos in osteoporosis trials?

C. Zerbini, E. Lewiecki, N. A. Silva, 2006, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

FRAX-based intervention and assessment thresholds in seven Latin American countries

J. Kanis, E. Denova-Gutiérrez, H. Johansson, 2018, Osteoporosis International.

Tofacitinib for the treatment of rheumatoid arthritis

C. Zerbini, C. Zerbini, A. Lomonte, 2012, Expert review of clinical immunology.